Internal Reference Number: FOI_6937
Date Request Received: 28/12/2022 00:00:00
Date Request Replied To: 16/01/2023 00:00:00
This response was sent via: By Email
Request Summary: venetoclax used in treatment for AML and CLL
Request Category: Companies
| Question Number 1: Please see attached questionnaire | |
| Answer To Question 1: Please see attached documents. To accompany this answer to question 1 please also see the documents listed below:  AzacitidineSC-Venetoclax.pdf CytarabineSC-Venetoclax.pdf ObinutuzumabVenetoclax-LowRisk.pdf VenetoclaxHigh.pdf VenetoclaxLow.pdf VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf VR-RituximabVenetoclax-Cycle-2-Onwards.pdf Venetoclax used in AML and CLL FOI 6937.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at ÃÛÌÒÓ°Ïñ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ÃÛÌÒÓ°Ïñ Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
